TCMD Overview

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.

Wall Street analysts forecast TCMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCMD is31.67 USD with a low forecast of 28.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tactile Systems Technology Inc revenue for the last quarter amounts to 103.59M USD, increased 21.04

Tactile Systems Technology Inc. EPS for the last quarter amounts to 0.46 USD, increased 15.00

Tactile Systems Technology Inc (TCMD) has 1086 emplpoyees as of March 21 2026.

Today TCMD has the market capitalization of 585.66M USD.